Acknowledgements. - Valuable support for the Forum came from the Cancer Research Campaign, from Johnson Matthey & Co., and from U. K. pharmaceutical companies - Beechams, Glaxo, ICI and Smith, Kline & French. Moreover, some speakers came without full financial coverage. The choice of presentations was guided by Honorary Advisers including Drs. S.H. Curry (Chairman), J.A.F. de Silva, L.E. Martin, J. Chamberlain and G.G. Skellern. Drs. Jim Leppard and Joan Reid are thanked for Index drafting. As mentioned in the text, some Figs. have already appeared in journals, whose publishers (e.g. Elsevier, Dekker, Preston) are thanked: sources include Journal of Chroma tography, Journal of Liquid Chromatography and Journal of Chromatographic Science, also (art. E-S) a Wiley book edited by M. Trimble. Abbreviations.- In connection with HPLC ('LC' is a pet aver sion) this Editor has often deplored the upstart use of 'ECD'-a term hallowed by its GC usage as in art. F -2 later in the book. To connote 'electrochemical' the term 'EC' is now used, but 'ECD' is reserved for the electron-capture detector. Other abbreviations which, although well known, are generally defined in each article concerned include NP, normal-phase [HPLC); RP, reverse(d)-phase; i.s., internal standard; MS, mass spectrometry (EI, electron-impact; CI, chemic,al-ionization); RIA, radioimmunoassay; UV, ultraviolet (usually absorbance).

Inhalt
#A Sample Handling and Usefulness of Isotopes.- #A-1 Separation science applied to analyses on biological samples.- #A-2 Sample handling in forensic toxicology.- #A-3 Stable isotopes in pharmacokinetic studies.- #A-4 Isotope-labelled materials as internal standards.- #NC(A) NOTES and COMMENTS related to the foregoing topics.- #NC(A)-1 Approaches for determining ethylenediamine and its metabolites: use of [14C]- and [D4]-ethylenediamine.- #NC(A)-2 Selective sample preparation techniques for trace analysis.- #NC(A)-3 Simplified approaches to the HPLC determination of drugs in biological samples.- #B Strategies for HPLC (Other Than Detection) and for TLC.- #B-1 Development and application of an HPLC pre-concentration device suitable for large amounts of biological sample.- #B-2 Multi-solvent optimization of HPLC separations.- #B-3 Optimization strategies for chromatographic analysis of multi-component mixtures.- #B-4 Reversed-phase TLC on alkyl-bonded and paraffin-coated silica gel.- #NC(B) NOTES and COMMENTS related to the foregoing topics.- #NC(B)-1 Chemically bonded stationary phases in (HP)TLC.- #NC(B)-2 TLC as a pilot technique for reversed-phase HPLC.- #C HPLC Detection, and Determination of Metal-Complex Drugs.- #C-1 Comparative performance of different HPLC systems with electrochemical detection.- #C-2 Specific element chromatographic detection by plasma spectral emission, as applied to organometallies and gold-containing drugs.- #C-3 HPLC-electrochemical determination of cis-platinum anti-cancer drugs.- #C-4 HPLC analysis of cisplatin analogues in biological fluids.- #C-5 The therapeutic use of gold compounds: analytical aspects.- #C-6 Clinical analysis of divalent platinum complexes with anti-neoplastic activity l6l.- #C-7 Solid phase derivatization reactions inHPLC.- #NC(C) NOTES and COMMENTS related to the foregoing topics l8l.- #NC(C)-1 Post-column reaction detectors for trace analysis in HPLC.- #NC(C)-2 Post-column reaction with ferric chloride for the detection of D-penicillamine.- #NC(C)-3 An evaluation of a two-electrode coulometric detector.- #NC(C)-4 A comparison of the moving belt and direct liquid introduction interfaces for HPLC-MS of ranitidine and its metabolites.- #D Tamoxifen and Other Anti-Cancer Drugs.- #D-1 Determination of the anti-cancer drug amsacrine in biological fluids by HPLC.- #D-2 Over-view of problems in determining tamoxifen levels in biological samples.- #D-3 Analysis of tamoxifen and its metabolites.- #D-4 HPLC methodology for therapeutic monitoring of tamoxifen and two major metabolites in blood and tissues.- #D-5 Analyses for tamoxifen, its metabolites and endogenous oestrogens in blood plasma and tumour tissue.- #NC(D) NOTES and COMMENTS related to the foregoing topics.- #NC(D)-1 Determination of tamoxifen and N-desmethyltamoxifen in plasma by HPLC.- #NC(D)-2 Identification of adriamycin and its metabolites in human and animal tissues and blood.- #NC(D)-3 Antibodies to deoxycytidine triphosphate (dCTP) suitable for its radioimmunoassay.- #NC(D)-4 Combined RIA/HPLC of methotrexate and its metabolites.- #NC(D)-5 Radioimmunoassay of methotrexate.- #E Ligand Methods for Drugs in Forensic and other Contexts.- #E-1 Radioimmunoassay in forensic science.- #E-2 Spin immunoassay for drug determination.- #E-3 Advent and present-day status of ligand methods.- #E-4 Radioreceptor assay of anticholinergic drugs in biological fluids.- #E-5 Receptor binding and HPLC analysis of benzodiazepines in a clinical laboratory.- #NC(E) NOTES and COMMENTS related to the foregoing topics.- #NC(E)-1 Assay of secoverine and active metabolites: comparison of stable isotope dilution with receptor binding assay.- #NC(E)-2 Some trends in ligand methods, including fluoroimmunoassay.- #NC(E)-3 Plasma morphine: comparison of results obtained by HPLC and RIA.- #F Various Analytes in Biological and Forensic Samples.- #F-1 HPLC with electrochemical detection: applications for the neurosciences.- #F-2 Gas chromatography with electron-capture detection for measurement of bioactive amines in biological samples.- #F-3 Analysis of the metabolites of bumetanide in urine by HPLC.- #F-4 Assay of compounds of forensic interest.- #F-5 Detection of solvent abuse by direct mass spectrometry on expired air.- #NC(F) NOTES and COMMENTS related to the foregoing topics.- #NC(F)-1 Explosives and other nitro compounds determined by liquid chromatography with photolysis-electrochemical detection.- #NC(F)-2 Nitroglycerin assay in plasma by thermal energy analyzer.- #NC(F)-3 A comparison of HPLC-thermal energy analysis and GC- electron capture detection for determining isosorbide dinitrate and its mononitrate metabolites in human plasma.- #G Analytical Quality Assurance.- #G-1 The role of external quality assessment schemes in the determination of plasma drug levels.- #G-2 Validation of bioanalytical procedures: an example.- #NC(G) NOTES and COMMENTS related to the foregoing topics.- #NC(G)-1 GLP in a chemical-pharmaceutical company: current status and experiences in analytical and drug disposition department.- #NC(G)-2 Quality control systems for routine drug analysis.- Analyte Index.- General Index.- Corrections to vols. 12 & 13.